stockportfolio.pro
BioCryst Pharmaceuticals, Inc. (BCRX)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
BioCryst Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.35M | $25.19M | $20.65M | $48.84M | $17.81M | $157.17M | $270.83M | $331.41M | $450.71M | $874.84M |
| Gross profit | $24.06M | $24.04M | — | $45.11M | $16.26M | $149.94M | $264.23M | $326.93M | $438.44M | $855.76M |
| Net income | $-55.14M | $-65.78M | $-101.25M | $-108.90M | $-182.81M | $-184.06M | $-247.12M | $-226.54M | $-88.88M | $263.86M |
| Net margin | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
Source: BioCryst Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into BCRX stock?
At today's market cap of $2.13B, BioCryst Pharmaceuticals, Inc. is priced for free-cash-flow growth of about -8.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $344.90M from the FY ending 2025-12-31). For comparison, revenue 117.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of BioCryst Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BCRX in your portfolio →
BioCryst Pharmaceuticals, Inc. financial history by metric
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc. — frequently asked questions
What is BioCryst Pharmaceuticals, Inc.'s revenue?
BioCryst Pharmaceuticals, Inc. (BCRX) reported revenue of $874.84M for fiscal year 2025, up 94.1% from the prior year, according to its SEC filings.
Is BioCryst Pharmaceuticals, Inc. profitable?
Yes. BCRX earned net income of $263.86M in fiscal 2025, a net margin of 30.2%.
What is BCRX's P/E ratio?
BioCryst Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is BioCryst Pharmaceuticals, Inc. growing?
BCRX's revenue grew at roughly 117.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does BioCryst Pharmaceuticals, Inc. have?
As of fiscal year 2025, BCRX carried roughly $427.23M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BioCryst Pharmaceuticals, Inc.'s gross margin?
BCRX's gross margin was 97.8% in fiscal 2025 — gross profit of $855.76M on revenue of $874.84M.
What is BioCryst Pharmaceuticals, Inc.'s market cap?
BioCryst Pharmaceuticals, Inc. (BCRX) has a market capitalization of about $2.13B, based on the latest data in our nightly-refreshed cache.
When does BioCryst Pharmaceuticals, Inc.'s fiscal year end?
BCRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BCRX stock?
At today's market cap of $2.13B, BioCryst Pharmaceuticals, Inc. is priced for free-cash-flow growth of about -8.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $344.90M from the FY ending 2025-12-31). For comparison, revenue 117.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from BioCryst Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.